Health Encyclopedia

Primary amyloidosis

Definition

Primary amyloidosis is a disorder in which protein fibers are deposited in tissues and organs, harming them.

Alternative Names

Amyloid - primary

Causes, incidence, and risk factors

The cause of primary amyloidosis is unknown, but the condition is related to abnormal production of antibodies by a type of immune cell called plasma cells.

The symptoms depend on the organs affected by the deposits. These organs can include the tongue, intestines, skeletal and smooth muscles, nerves, skin, ligaments, heart, liver, spleen, and kidneys.

Primary amyloidosis can result in conditions that include:

The deposits invade the affected organs, causing them to become stiff, which decreases their ability to function. Secondary amyloidosis can be caused by infection, inflammatory diseases, and sometimes cancer.

Risk factors have not been identified. Primary amyloidosis is rare. It is related to the malignant plasma cell disorder multiple myeloma.

Symptoms

Enlarged tongue
Fatigue
Irregular heart rhythm
Numbness of hands and feet
Shortness of breath
Skin changes
Swallowing difficulties
Swelling in the arms and legs
Weak hand grip
Weight loss

Additional symptoms that may be associated with this disease:

Clay-colored stools
Decreased urine output
Diarrhea
Hoarseness or changing voice
Joint pain
Other tongue problems
Weakness

Signs and tests

Your doctor may discover that you have an enlarged liver or spleen. You may also have signs of heart failure.

If specific organ damage is suspected, your doctor may order tests to confirm amyloidosis of that organ. For example:

Abdominal ultrasound may reveal enlarged liver or spleen.
A biopsy of a tissue or organ will be positive for amyloid. A skin biopsy that includes subcutaneous fat, a rectal mucosa biopsy, or a bone marrow biopsy can help confirm the diagnosis.
A heart evaluation may reveal arrhythmias, abnormal heart sounds, or signs of heart failure.
- An ECG shows abnormalities.
- An echocardiogram shows poor motion of the heart wall, due to a stiff heart muscle (cardiomyopathy).
Evaluation for carpal tunnel syndrome may reveal involvement of the nerve:
- Hand grips are weak because of weakness of the thumb.
- Nerve conduction velocity shows a conduction block.
Kidney function evaluation may reveal kidney failure or nephrotic syndrome (too much protein in the urine).
- BUN is increased.
- Serum creatinine is increased.
- Urinalysis shows protein, casts, or fat bodies.

This disease may also alter the results of the following tests:

Treatment

Some patients with primary amyloidosis respond to chemotherapy directed at the abnormal plasma cells. Stem cell transplantation may be used, as in multiple myeloma.

In secondary amyloidosis, aggressive treatment of the underlying disease can improve symptoms and/or slow progression of disease. Complications such as heart failure, kidney failure, and other problems can sometimes be treated as necessary.

Expectations (prognosis)

The severity of the disease depends upon the organs affected. Heart and kidney involvement may lead to organ failure and death. Systemic involvement is associated with death within 1 to 3 years.

Complications

Death
Endocrine failure (hormonal disorder)
Heart failure
Kidney failure
Respiratory failure

Calling your health care provider

Call your health care provider if symptoms consistent with primary amyloidosis develop.

If you know you have primary amyloidosis, call your health care provider if difficulty breathing, persistent swelling of the ankles or other areas, decreased urine output, or other symptoms occur. This may indicate that complications have developed.

Prevention

There is no known prevention.

References

Buxbaum JN. The Amyloidoses. In: Goldman L, Ausiello D. Cecil Textbook of Medicine. 22nd ed. Philadelphia, Pa: WB Saunders; 2004.

Hoffman R, Benz Jr. EJ, Shattil SJ, et al., eds. Hematology: Basic Principles and Practice. 4th ed. Philladelphia, Pa: Churchill Livingston; 2005:1540-48.

Review Date:2/26/2007
Reviewed By:William Matsui, MD, Assistant Professor of Oncology, Division of Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD. Review provided by VeriMed Healthcare Network.

ADAM Quality A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process. A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The Agency for Health Care Administration (Agency) and this website do not claim the information on, or referred to by, this site is error free. This site may include links to websites of other government agencies or private groups. Our Agency and this website do not control such sites and are not responsible for their content. Reference to or links to any other group, product, service, or information does not mean our Agency or this website approves of that group, product, service, or information.

Additionally, while health information provided through this website may be a valuable resource for the public, it is not designed to offer medical advice. Talk with your doctor about medical care questions you may have.